Genome and transcriptome sequences from hundreds of pediatric cancer cases led to somatic mutations and fusions suspected of producing potentially targetable antigens.
When investigators retraced recurrent mutations, expression changes, and methylation shifts in hundreds of Wilms tumor case, they identified two main pathways.
Hospital will partner with several other institutions in this effort to support data-driven research into pediatric cancers and structural birth defects.
The study is the pediatric counterpart to an ongoing precision medicine study in cancer patients 18 years and older.
With mutation, expression, and epigenetic features from hundreds of medulloblastoma tumors, researchers characterized key features of brain tumor subtypes.
Independent research teams took a look at the mutations, gene fusions, and other alterations that may inform pediatric T-ALL treatment and outcome predictions.
Suspicious variants were uncovered through analyses of pediatric cancer survivors from the St. Jude Lifetime Cohort Study and Childhood Cancer Survivor Study.
The lab-developed test will use Thermo Fisher Scientific's Ion sequencing platform and will be applicable to most childhood cancers.
Researchers hope to identify exosomal biomarkers that can predict or detect cancer recurrence and metastasis at its earliest stages.
The study showed that targeted sequencing was feasible, identified many clinically relevant alterations, and directed effective targeted therapy in several cases.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.